AU2002229639A1 - Camelidae antibody arrays - Google Patents

Camelidae antibody arrays

Info

Publication number
AU2002229639A1
AU2002229639A1 AU2002229639A AU2963902A AU2002229639A1 AU 2002229639 A1 AU2002229639 A1 AU 2002229639A1 AU 2002229639 A AU2002229639 A AU 2002229639A AU 2963902 A AU2963902 A AU 2963902A AU 2002229639 A1 AU2002229639 A1 AU 2002229639A1
Authority
AU
Australia
Prior art keywords
antibody arrays
camelidae
cell
camelidae antibody
tissue extracts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002229639A
Inventor
Ilse Landa
Cornelis Theodorus Verrips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JOHANNES JOSEPH WILHELMUS DE H
Original Assignee
JOHANNES JOSEPH WILHELMUS DE H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JOHANNES JOSEPH WILHELMUS DE H filed Critical JOHANNES JOSEPH WILHELMUS DE H
Publication of AU2002229639A1 publication Critical patent/AU2002229639A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Protein arrays are provided comprising single domain antibodies obtainable from Camelidae which are capable of detecting even minor changes in the expression of proteins in cell and tissue extracts and having an optimal signal to noise ratio by removing non-informative abundant proteins from said cell or tissue extracts.
AU2002229639A 2000-12-13 2001-12-03 Camelidae antibody arrays Abandoned AU2002229639A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00311142 2000-12-13
EP00311142.4 2000-12-13
PCT/EP2001/014471 WO2002048193A2 (en) 2000-12-13 2001-12-03 Camelidae antibody arrays

Publications (1)

Publication Number Publication Date
AU2002229639A1 true AU2002229639A1 (en) 2002-06-24

Family

ID=8173443

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002229639A Abandoned AU2002229639A1 (en) 2000-12-13 2001-12-03 Camelidae antibody arrays

Country Status (7)

Country Link
US (2) US20040053340A1 (en)
EP (1) EP1360207B1 (en)
AT (1) ATE513854T1 (en)
AU (1) AU2002229639A1 (en)
DK (1) DK1360207T3 (en)
ES (1) ES2368623T3 (en)
WO (1) WO2002048193A2 (en)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4213586B2 (en) * 2001-09-13 2009-01-21 株式会社抗体研究所 Camel antibody library production method
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
WO2005003326A2 (en) * 2003-03-28 2005-01-13 Receptors Llc. Artificial receptors including reversibly immobilized building blocks and methods
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060024746A1 (en) * 2004-07-14 2006-02-02 Artann Laboratories, Inc. Methods and devices for optical monitoring and rapid analysis of drying droplets
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006055371A2 (en) * 2004-11-16 2006-05-26 Alexion Pharmaceuticals, Inc. Functional screening of antibody libraries
FR2879605B1 (en) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
PL1888641T3 (en) 2005-05-18 2012-05-31 Ablynx Nv Serum albumin binding proteins
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
DE102005023617A1 (en) 2005-05-21 2006-11-23 Aspre Ag Method for mixing colors in a display
PT3028716T (en) 2006-10-10 2020-11-23 Regenesance B V Complement inhibition for improved nerve regeneration
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2308514B1 (en) 2007-03-23 2013-06-05 to-BBB Holding B.V. Conjugates for targeted drug delivery across the blood-brain barrier
EP2173772A2 (en) 2007-07-03 2010-04-14 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
JP2010533004A (en) * 2007-07-13 2010-10-21 バク アイピー ベスローテン フェンノートシャップ Single domain antigen binding protein that binds to mammalian IgG
WO2009030285A1 (en) * 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US20090305899A1 (en) * 2007-11-16 2009-12-10 Invitrogen Incorporated Compositions and methods for determining immune status
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CN102056945A (en) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 Amino acid sequences directed against the Notch pathways and uses thereof
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
ES2864956T3 (en) 2009-04-30 2021-10-14 Ablynx Nv Procedure for the production of domain antibodies
HUE051430T2 (en) 2009-07-10 2021-03-01 Ablynx Nv Method for the production of variable domains
PL3438126T3 (en) 2009-09-03 2021-03-08 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CN105380904A (en) 2010-02-11 2016-03-09 埃博灵克斯股份有限公司 Methods and compositions for the preparation of aerosols
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
PL2632946T3 (en) 2010-10-29 2018-06-29 Ablynx N.V. Method for the production of immunoglobulin single variable domains
WO2012105833A1 (en) * 2011-02-01 2012-08-09 Bac Ip B.V. Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
US9505840B2 (en) 2011-05-27 2016-11-29 Ablynx N.V. Inhibition of bone resorption with RANKL binding peptides
JP2014525736A (en) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． Immunoglobulin single variable domain for IgE
WO2013041901A1 (en) * 2011-09-20 2013-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing single domain antibody microarrays
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
CA2874309C (en) 2012-05-24 2021-06-15 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US20140046722A1 (en) * 2012-08-10 2014-02-13 Sample6 Technologies, Inc. System for on-site environment monitoring
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
PT2951201T (en) 2013-01-30 2018-01-09 Univ Brussel Vrije Novel chimeric polypeptides for screening and drug discovery purposes
EP3590578A1 (en) 2013-02-05 2020-01-08 VIB vzw Muscarinic acetylcholine receptor binding agents and uses thereof
CA2906259C (en) 2013-03-15 2022-12-06 Vib Vzw Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases
JP6388917B2 (en) 2013-04-29 2018-09-12 アグロサーフエ・エン・フエー Agrochemical composition comprising a polypeptide
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
FR3007411B1 (en) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech MONOCATENARY ANTIBODY TO CAMPHIDE HEAVY CHAIN AGAINST CHROMATIN AND USES THEREOF
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
US10233241B2 (en) 2014-01-30 2019-03-19 Vib Vzw Opioid receptor binding agents and uses thereof
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3180037A1 (en) 2014-07-29 2017-06-21 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
US9855348B2 (en) 2014-07-29 2018-01-02 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
EP3215624B1 (en) 2014-11-05 2023-11-29 Biotalys NV Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
PT3233910T (en) 2014-12-19 2020-03-17 Ablynx Nv Cysteine linked nanobody dimers
AU2016294858B2 (en) 2015-07-17 2022-08-11 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
RU2018122255A (en) 2015-11-27 2019-12-19 Аблинкс Нв CD40L INHIBITING POLYPEPTIDES
US11243214B2 (en) 2016-04-22 2022-02-08 Université Libre de Bruxelles Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
EP3452505A1 (en) 2016-05-02 2019-03-13 Ablynx NV Treatment of rsv infection
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
JP7222888B2 (en) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． T cell engaging polypeptides capable of binding CD123 and TCR alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
CA3054623A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
US20200190216A1 (en) 2017-06-02 2020-06-18 Merck Patent Gmbh Mmp13 binding immunoglobulins
EP3630847A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Adamts binding immunoglobulins
AU2018277310A1 (en) 2017-06-02 2019-12-12 Ablynx Nv Aggrecan binding immunoglobulins
TWI826376B (en) 2017-06-02 2023-12-21 德商麥克專利有限公司 Polypeptides binding adamts5, mmp13 and aggrecan
US11155607B2 (en) 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
EP3470436A1 (en) * 2017-10-11 2019-04-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Anti-igg nanobodies
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
EP3758742A1 (en) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
CN116942851A (en) 2018-03-23 2023-10-27 布鲁塞尔自由大学 Wnt signaling agonist molecules
JP2021519093A (en) 2018-03-27 2021-08-10 ユーエムシー ユトレヒト ホールディング ビー．ブイ． Targeted thrombolysis for the treatment of microvascular thrombosis
CN108659131B (en) * 2018-05-28 2021-09-14 长春力太生物技术有限公司 anti-CEACAM-5 single-domain antibody and application thereof
JP2022530549A (en) 2019-04-29 2022-06-29 コンフォ セラピューティクス エヌ．ブイ． Screening methods and assays for use with transmembrane proteins, especially GPCRs
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
US20220228116A1 (en) 2019-05-28 2022-07-21 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
US11414785B2 (en) 2019-08-13 2022-08-16 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish IgNAR derived binding domains
US20220380456A1 (en) 2019-10-21 2022-12-01 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
WO2021095031A2 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP4110794A1 (en) 2020-02-25 2023-01-04 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
CN115915939A (en) 2020-03-31 2023-04-04 生物催化公司 Antifungal polypeptides
JP2023523600A (en) 2020-04-22 2023-06-06 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド Single variable domain antibodies and derivatives thereof targeting human programmed cell death ligand 1 (PD-L1)
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP4189060A1 (en) 2020-07-31 2023-06-07 Biotalys NV Expression host
KR20220026401A (en) 2020-08-25 2022-03-04 주식회사 에프티넷 Aluminum alloy for flux-free brazing and brazing method using the same
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
IL301581A (en) 2020-09-25 2023-05-01 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (en) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ LTBR agonists in combination therapy against cancer
EP4263602A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
US20240052045A1 (en) 2020-12-24 2024-02-15 Vib Vzw Murine cross-reactive human ccr8 binders
US20240052044A1 (en) 2020-12-24 2024-02-15 Vib Vzw Non-blocking human ccr8 binders
CA3206304A1 (en) 2020-12-24 2022-06-30 Vib Vzw Human ccr8 binders
CN117794566A (en) 2021-02-05 2024-03-29 Vib研究所 Sha Bei viral binding agents
KR20230141853A (en) 2021-02-05 2023-10-10 브이아이비 브이지더블유 Sabecovirus binding agent
EP4294407A1 (en) 2021-02-17 2023-12-27 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
CA3225194A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
EP4365199A1 (en) 2021-06-29 2024-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Cd16 antibody and use thereof
EP4365203A1 (en) * 2021-07-01 2024-05-08 Ningbo T-MAXIMUM Biopharmaceuticals Co., Ltd. Antigen-binding polypeptide targeting b7h3 and application thereof
CN117751143A (en) 2021-07-30 2024-03-22 山东先声生物制药有限公司 anti-PVRIG/anti-TIGIT bispecific antibodies and uses
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
TW202342508A (en) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 and CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023148291A1 (en) 2022-02-02 2023-08-10 Biotalys NV Methods for genome editing
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081244A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US5389523A (en) * 1988-05-31 1995-02-14 The United States Of Americas, As Represented By The Secretary Of Commerce Liposome immunoanalysis by flow injection assay
US5993935A (en) * 1991-10-11 1999-11-30 3M Innovative Properties Company Covalently reactive particles incorporated in a continous porous matrix
ZA94916B (en) * 1993-02-10 1995-08-10 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
DK0698097T3 (en) * 1993-04-29 2001-10-08 Unilever Nv Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins
US5485277A (en) * 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
EP0739981A1 (en) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5852127A (en) * 1996-07-09 1998-12-22 Rensselner Polytechnic Institute Modification of porous and non-porous materials using self-assembled monolayers
AU740830B2 (en) * 1998-01-29 2001-11-15 Glaucus Proteomics B.V. High density arrays for proteome analysis and methods and compositions therefor
BR9907950A (en) * 1998-02-19 2001-12-18 Xcyte Therapies Inc Compositions and processes for regulating lymphocyte activation
US6858210B1 (en) * 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2001040310A2 (en) * 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
DK1233987T3 (en) * 1999-11-29 2009-09-28 Bac Ip B V Immobilized single-domain antigen-binding molecules
US7037676B2 (en) * 2000-03-21 2006-05-02 Bristol-Myers Squibb Drosophila tumor necrosis factor class molecule polynucleotides and variants thereof

Also Published As

Publication number Publication date
EP1360207A2 (en) 2003-11-12
WO2002048193A3 (en) 2003-08-14
US20040053340A1 (en) 2004-03-18
DK1360207T3 (en) 2011-09-05
EP1360207B1 (en) 2011-06-22
US20140256579A1 (en) 2014-09-11
ES2368623T3 (en) 2011-11-18
ATE513854T1 (en) 2011-07-15
WO2002048193A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2002229639A1 (en) Camelidae antibody arrays
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
DK2316852T3 (en) Stabilized single-domain antibodies
ATE304592T1 (en) AUTOMATION IN PROTEIN DESIGN THROUGH PROTEIN LIBRARIES
DE60113393D1 (en) ADHESIVE COMPOSITIONS FROM VEGETABLE PROTEIN
CA2250141A1 (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
HUP0500444A2 (en) Hcv antigen/antibody combination assay
WO2004041865A3 (en) Stabilized single domain antibodies
HUP0200546A2 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
DE60141476D1 (en) PROCESSING OF ACOUSTIC MICRO-PICTURE SIGNALS IN THE FREQUENCY AREA
WO2003062402A3 (en) Use of collections of binding sites for sample profiling and other applications
WO2005019470A3 (en) Detecting and profiling molecular complexes
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2001057198A3 (en) Methods of generating protein expression arrays and the use thereof in rapid screening
FR2816410B1 (en) ESM-1 PROTEIN DETECTION KIT AND DETECTION METHOD USING THE SAME
TR200103666T2 (en) Weakened pestivir
CA2406443A1 (en) Method for quantification of akt protein expression
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
AU2003242106A1 (en) Detection kit, assay plate to be used therein, detection method, evaluation method, polyclonal antibody of frog vitellogenin and procss for producing the same
WO2002036635A3 (en) Monoclonal antibodies for assaying lipid transfer proteins